Impax Laboratories

Impax Laboratories to cut workforce

Friday, June 7, 2013 01:57 PM

Impax Laboratories, a technology-based specialty pharmaceutical company, will implement a reduction in its workforce as a part of efforts to streamline its operations in response to the need to reduce expenses and adapt to changing market conditions. The reduction primarily affects manufacturing operations and is intended to reduce Impax's cost structure and scale the organization appropriately for its current needs.

More... »

GSK, Impax Pharmaceuticals terminate collaboration on IPX066

Monday, April 29, 2013 02:25 PM

Impax Pharmaceuticals, the brand products division of Impax Laboratories, and GlaxoSmithKline (GSK) are terminating their collaboration for the development and commercialization of IPX066 outside the U.S. and Taiwan.

More... »

Fang joins SRI as director of clinical manufacturing

Thursday, December 8, 2011 02:09 PM

Jia-Hwa Fang, Ph.D., has joined SRI's biosciences division as director of clinical manufacturing. In this new role, he will lead a team to transfer and scale-up R&D, Good Laboratory Practice (GLP), and pilot formulations for early stage clinical
trial materials in compliance with Good Manufacturing Practices (GMP). He will be responsible for developing technical, quality, and project specifications for studies in SRI's pharmaceutical clinical manufacturing facility.

More... »

Impax receives grant from Michael J. Fox Foundation

Wednesday, July 20, 2011 11:39 AM

Impax Pharmaceuticals has been awarded funding of up to $400,000 by The Michael J. Fox Foundation for ongoing clinical research of its investigational carbidopa-levodopa extended release (CD-LD ER) product IPX066, which is intended to treat the motor symptoms of Parkinson's disease.

More... »

Impax Labs' Parkinson's drug aces late-stage clinical trial

Friday, March 18, 2011 01:41 PM

Hayward, Calif.-based Impax Laboratories said the Parkinson's drug it in-licensed from GlaxoSmithKline last year—its second attempt at an extended-release version of caribidopa-levadopa—beat out the standard of care for controlling a key symptom of the disease in a late-stage study, according to FiercePharma.

More... »